Access the full text.
Sign up today, get DeepDyve free for 14 days.
C. Thompson, T. Shanafelt, C. Loprinzi (2003)
Andropause: symptom management for prostate cancer patients treated with hormonal ablation.The oncologist, 8 5
F. Schröder, Monique J, Melissa Center, A. Jemal, J. Lortet-Tieulent, Elizabeth Ward, J. Ferlay, O. Brawley, F. Bray
Platinum Priority – Review – Prostate Cancer International Variation in Prostate Cancer Incidence and Mortality Rates
S. Culos-Reed, John Robinson, H. Lau, Lynette Stephenson, M. Keats, S. Norris, Greg Kline, P. Faris (2010)
Physical activity for men receiving androgen deprivation therapy for prostate cancer: benefits from a 16-week interventionSupportive Care in Cancer, 18
Daniel Buysse, C. Reynolds, T. Monk, S. Berman, D. Kupfer (1989)
The Pittsburgh sleep quality index: A new instrument for psychiatric practice and researchPsychiatry Research, 28
S. Seidman, B. Walsh (1999)
Testosterone and depression in aging men.The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry, 7 1
MM Center, A Jemal, J Lortet-Tieulent, E Ward, J Ferlay, O Brawley (2012)
International variation in prostate cancer incidence and mortality ratesEur Urol, 61
A Heidenreich, PJ Bastian, J Bellmunt, M Bolla, S Joniau, T Kwast, M Mason, V Matveev, T Wiegel, F Zattoni, N Mottet (2014)
European Association of Urology. EAU guidelines on prostate cancer. Part II: treatment of advanced, relapsing, and castration-resistant prostate cancerEur Urol, 65
L. Walker, S. Tran, J. Robinson (2013)
Luteinizing hormone--releasing hormone agonists: a quick reference for prevalence rates of potential adverse effects.Clinical genitourinary cancer, 11 4
Kristine Donovan, P. Jacobsen (2007)
Fatigue, depression, and insomnia: evidence for a symptom cluster in cancer.Seminars in oncology nursing, 23 2
J. Savard, S. Hervouet, H. Ivers (2013)
Prostate cancer treatments and their side effects are associated with increased insomniaPsycho‐Oncology, 22
K. Rove, E. Crawford (2014)
Traditional androgen ablation approaches to advanced prostate cancer: new insights.The Canadian journal of urology, 21 2 Supp 1
M. Shores, Victoria Moceri, K. Sloan, A. Matsumoto, D. Kivlahan (2005)
Low testosterone levels predict incident depressive illness in older men: effects of age and medical morbidity.The Journal of clinical psychiatry, 66 1
W. Pirl, Gabrielle Siegel, Melissa Goode, Matthew Smith (2002)
Depression in Men Receiving Androgen Deprivation Therapy for Prostate Cancer: A Pilot StudyPsycho‐Oncology, 11
L. Krupp, N. Larocca, J. Muir-Nash, A. Steinberg (1989)
The fatigue severity scale. Application to patients with multiple sclerosis and systemic lupus erythematosus.Archives of neurology, 46 10
P. Perry, W. Yates, Richard Williams, A. Andersen, J. MacIndoe, B. Lund, T. Holman (2002)
Testosterone therapy in late-life major depression in males.The Journal of clinical psychiatry, 63 12
A. Saini, A. Berruti, C. Cracco, E. Sguazzotti, F. Porpiglia, L. Russo, V. Bertaglia, R. Picci, Manuela Negro, A. Tosco, S. Campagna, R. Scarpa, L. Dogliotti, P. Furlan, L. Ostacoli (2013)
Psychological distress in men with prostate cancer receiving adjuvant androgen-deprivation therapy.Urologic oncology, 31 3
Christina Wang, G. Alexander, N. Berman, B. Salehian, T. Davidson, V. McDonald, B. Steiner, L. Hull, C. Callegari, R. Swerdloff (1996)
Testosterone replacement therapy improves mood in hypogonadal men--a clinical research center study.The Journal of clinical endocrinology and metabolism, 81 10
M. Svetel, J. Jović, T. Pekmezović, V. Kostic (2015)
Quality of life in patients with primary restless leg syndrome: community-based studyNeurological Sciences, 36
V. Shahinian, Y. Kuo, J. Freeman, J. Goodwin (2006)
Risk of the "androgen deprivation syndrome" in men receiving androgen deprivation for prostate cancer.Archives of internal medicine, 166 4
H. Jim, Jong Park, Jennifer Permuth‐Wey, Maria Rincon, K. Phillips, B. Small, P. Jacobsen (2012)
Genetic predictors of fatigue in prostate cancer patients treated with androgen deprivation therapy: Preliminary findingsBrain, Behavior, and Immunity, 26
Kathleen Light, N. Agarwal, E. Iacob, A. White, A. Kinney, Timothy VanHaitsma, Hannah Aizad, R. Hughen, L. Bateman, A. Light (2013)
Differing leukocyte gene expression profiles associated with fatigue in patients with prostate cancer versus chronic fatigue syndromePsychoneuroendocrinology, 38
M. Robichaud, G. Debonnel (2005)
Oestrogen and Testosterone Modulate the Firing Activity of Dorsal Raphe Nucleus Serotonergic Neurones in Both Male and Female RatsJournal of Neuroendocrinology, 17
C. Higano (2003)
Side effects of androgen deprivation therapy: monitoring and minimizing toxicity.Urology, 61 2 Suppl 1
S. Seidman, J. Rabkin (1998)
Testosterone replacement therapy for hypogonadal men with SSRI-refractory depression.Journal of affective disorders, 48 2-3
R. Pakzad, A. Mohammadian-Hafshejani, M. Ghoncheh, I. Pakzad, H. Salehiniya (2015)
The incidence and mortality of prostate cancer and its relationship with development in AsiaProstate International, 3
Muhammad Bashir (2015)
Epidemiology of Prostate Cancer.Asian Pacific journal of cancer prevention : APJCP, 16 13
L. Hanisch, Nalaka Gooneratne, Ketki Soin, Philip Gehrman, David Vaughn, James Coyne (2011)
Sleep and daily functioning during androgen deprivation therapy for prostate cancer.European journal of cancer care, 20 4
M. Cherrier, S. Aubin, C. Higano (2009)
Cognitive and mood changes in men undergoing intermittent combined androgen blockade for non‐metastatic prostate cancerPsycho‐Oncology, 18
D. Storey, D. McLaren, M. Atkinson, I. Butcher, L. Frew, J. Smyth, M. Sharpe (2011)
Clinically relevant fatigue in men with hormone-sensitive prostate cancer on long-term androgen deprivation therapy.Annals of oncology : official journal of the European Society for Medical Oncology, 23 6
A. Beck, C. Ward, M. Mendelson, J. Mock, J. Erbaugh (1961)
An inventory for measuring depression.Archives of general psychiatry, 4
D. Hershman, J. Unger, J. Wright, S. Ramsey, C. Till, C. Tangen, W. Barlow, C. Blanke, I. Thompson, M. Hussain (2016)
Adverse Health Events Following Intermittent and Continuous Androgen Deprivation in Patients With Metastatic Prostate Cancer.JAMA oncology, 2 4
HJ Yue, JE Dimsdale (2010)
Psychooncology
U. Schweiger, M. Deuschle, B. Weber, Andreas Körner, C. Lammers, J. Schmider, U. Gotthardt, I. Heuser (1999)
Testosterone, gonadotropin, and cortisol secretion in male patients with major depression.Psychosomatic medicine, 61 3
P. Stone, J. Hardy, R. Huddart, R. A’Hern, M. Richards (2000)
Fatigue in patients with prostate cancer receiving hormone therapy.European journal of cancer, 36 9
P. Nguyen, S. Alibhai, S. Basaria, A. D'Amico, P. Kantoff, N. Keating, D. Penson, D. Rosario, B. Tombal, Matthew Smith (2015)
Adverse effects of androgen deprivation therapy and strategies to mitigate them.European urology, 67 5
S. Hervouet, J. Savard, H. Ivers, Marie-Hélène Savard (2013)
Depression and androgen deprivation therapy for prostate cancer: a prospective controlled study.Health psychology : official journal of the Division of Health Psychology, American Psychological Association, 32 6
M. Johns (1991)
A new method for measuring daytime sleepiness: the Epworth sleepiness scale.Sleep, 14 6
Androgen deprivation is a therapeutic option for patients with prostate cancer (PC). However, it has negative effects on sleep quality and psychological condition. Here, we evaluated the appearance of sleep disturbances in patients on androgen deprivation therapy (ADT). We administered Pittsburgh Sleep Quality Index (PSQI), Beck Depression Inventory (BDI), Epworth Sleepiness Scale (ESS), and Fatigue Severity Scale (FSS) to consecutive prostate cancer patients who had undergone radical prostatectomy and are presently either under adjuvant ADT or followed in an unmedicated program (non-ADT). The results of the tests in ADT and non-ADT groups in addition to the demographic data and the features of the malignancy were statistically compared. Of the 106 patients enrolled, 48 (45.3%) were receiving adjuvant ADT and 58 (54.7%) were not. Age, disease duration, and education levels showed no difference between the two groups. Compared with the non-ADT group, the patients receiving ADT showed higher levels of depression, worse quality of sleep, and more severe fatigue (p < 0.001, for each). There was no significant difference among the two groups regarding excessive daytime sleepiness (p = 0.856). The mean PSQI scores showed a positive correlation with BDI and FSS scores (r = 0.710, p < 0.001; r = 0.528, p < 0.001, respectively). Additionally, ADT was strongly associated with PSQI and FSS scores at multivariate analysis (p = 0.037, p = 0.043, respectively). We conclude that PC patients receiving ADT are likely to be fatigued, more depressed, and had poorer sleep quality. Our study showed that receiving ADT therapy is strongly associated with poor sleep quality and fatigue.
Neurological Sciences – Springer Journals
Published: May 8, 2017
Read and print from thousands of top scholarly journals.
Already have an account? Log in
Bookmark this article. You can see your Bookmarks on your DeepDyve Library.
To save an article, log in first, or sign up for a DeepDyve account if you don’t already have one.
Copy and paste the desired citation format or use the link below to download a file formatted for EndNote
Access the full text.
Sign up today, get DeepDyve free for 14 days.
All DeepDyve websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.